Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects

Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab

(2017) Federico Simonetta et al.   JOINT BONE SPINE

Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma

(2017) Hakan Demirci et al.   OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial

(2017) Divi Cornec et al.   ARTHRITIS CARE & RESEARCH

Neuroendocrine Dysfunction in Sjögren’s Syndrome

(2017) Athanasios G. Tzioufas et al.   NEUROIMMUNOMODULATION

In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI

(2016) Konstantina Delli et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study

(2016) A. Alunno et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren's syndrome

(2016) Morgane Milin et al.   JOINT BONE SPINE

Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome

(2016) Divi Cornec et al.   JOURNAL OF AUTOIMMUNITY

Defective DNA methylation in salivary gland epithelial acini from patients with Sjögren's syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration

(2016) O.D. Konsta et al.   JOURNAL OF AUTOIMMUNITY

The BAFFling effects of rituximab in lupus: danger ahead?

(2016) Michael R. Ehrenstein et al.   Nature Reviews Rheumatology

Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes

(2016) René Galien   Pharmacological Reports

Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

(2016) Francine Bertolais do Valle Souza et al.   PLoS One

Aquaporin gene therapy corrects Sjögren’s syndrome phenotype in mice

(2016) Zhennan Lai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sjögren syndrome

(2016) Pilar Brito-Zerón et al.   Nature Reviews Disease Primers

Clinical development of gene therapy: results and lessons from recent successes

(2016) Sandeep RP Kumar et al.   Molecular Therapy-Methods & Clinical Development

Immuno-ecology: how the microbiome regulates tolerance and autoimmunity

(2015) Alexandra Paun et al.   CURRENT OPINION IN IMMUNOLOGY

Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta

(2015) Sasha Bernatsky et al.   ENVIRONMENTAL RESEARCH

Advances in salivary gland gene therapy – oral and systemic implications

(2015) Bruce J Baum et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations

(2015) Pilar Brito-Zerón et al.   Expert Review of Clinical Immunology

Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia

(2015) Bin Jiang et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Refractory Primary Sjögren Syndrome Successfully Treated With Bortezomib

(2015) Juan Jakez-Ocampo et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Primary Sjögren's syndrome and occupational risk factors: A case–control study

(2015) Benjamin Chaigne et al.   JOURNAL OF AUTOIMMUNITY

TSP-1 Deficiency Alters Ocular Microbiota: Implications for Sjögren's Syndrome Pathogenesis

(2015) Marielle Terzulli et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

(2015) V Goede et al.   LEUKEMIA

Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome

(2015) Elena Pontarini et al.   RHEUMATOLOGY

Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study

(2015) Raphaèle Seror et al.   ARTHRITIS RESEARCH & THERAPY

Familial Risk of Sjögren's Syndrome and Co-aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study

(2015) Chang-Fu Kuo et al.   Arthritis & Rheumatology

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?

(2015) Valérie Devauchelle-Pensec et al.   PLoS One

Treatment of Primary Sjögren Syndrome With Rituximab

(2014) Valérie Devauchelle-Pensec et al.   ANNALS OF INTERNAL MEDICINE

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

(2014) P M Meiners et al.   ANNALS OF THE RHEUMATIC DISEASES

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

(2014) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

(2014) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

The efficacy of novel B cell biologics as the future of SLE treatment: A review

(2014) Ameer Kamal et al.   AUTOIMMUNITY REVIEWS

T cell epitope mimicry between Sjögren's syndrome Antigen A (SSA)/Ro60 and oral, gut, skin and vaginal bacteria

(2014) Agnieszka Szymula et al.   CLINICAL IMMUNOLOGY

Early events in Sjögren’s Syndrome pathogenesis: The importance of innate immunity in disease initiation

(2014) Jill M. Kramer   CYTOKINE

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus

(2014) William Stohl   EXPERT OPINION ON THERAPEUTIC TARGETS

Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial—an open-label, one-year, prospective study—Interim analysis of 32 patients for 24 weeks

(2014) Hiroto Tsuboi et al.   Modern Rheumatology

Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren’s syndrome

(2014) Francesco Ciccia et al.   RHEUMATOLOGY

Tear Cathepsin S as a Candidate Biomarker for Sjögren's Syndrome

(2014) Sarah F. Hamm-Alvarez et al.   Arthritis & Rheumatology

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

(2013) Xavier Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab Therapy for Primary Sjögren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis

(2013) E. William St.Clair et al.   ARTHRITIS AND RHEUMATISM

Inhibiting cathepsin S to treat SLE and lupus nephritis

(2013) Nicholas J. Bernard   Nature Reviews Rheumatology

Advances in understanding the pathogenesis of primary Sjögren's syndrome

(2013) Gaëtane Nocturne et al.   Nature Reviews Rheumatology

Evaluation of Histologic, Serologic, and Clinical Changes in Response to Abatacept Treatment of Primary Sjögren's Syndrome: A Pilot Study

(2013) Sabine Adler et al.   ARTHRITIS CARE & RESEARCH

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

(2013) Francesco Carubbi et al.   ARTHRITIS RESEARCH & THERAPY

Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica

(2013) Jennifer Graves et al.   Multiple Sclerosis and Related Disorders

Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab

(2012) P M Meiners et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

(2012) Jacques-Eric Gottenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies

(2012) James J. Driscoll et al.   Anti-Cancer Agents in Medicinal Chemistry

Endocrine alterations in primary Sjogren's syndrome: An overview

(2012) Clio P. Mavragani et al.   JOURNAL OF AUTOIMMUNITY

Pathogenesis of Sjögren’s syndrome: What we know and what we should learn

(2012) Athanasios G. Tzioufas et al.   JOURNAL OF AUTOIMMUNITY

Topical and systemic medications for the treatment of primary Sjögren's syndrome

(2012) Manuel Ramos-Casals et al.   Nature Reviews Rheumatology

Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical Trial

(2012) Katrine Brække Norheim et al.   PLoS One

BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands

(2012) L. Quartuccio et al.   RHEUMATOLOGY

Primary Sjogren syndrome

(2012) M. Ramos-Casals et al.   BMJ-British Medical Journal

Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry

(2011) A Mekinian et al.   ANNALS OF THE RHEUMATIC DISEASES

Neutropenia after rituximab treatment

(2011) Ofir Wolach et al.   CURRENT OPINION IN HEMATOLOGY

Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren’s Syndrome: A Retrospective Clinical Study

(2011) RODNEY P.E. POLLARD et al.   JOURNAL OF RHEUMATOLOGY

Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome

(2011) Michael Voulgarelis et al.   MEDICINE

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

(2011) P. Engel et al.   PHARMACOLOGICAL REVIEWS

Disturbance of cytokine networks in Sjögren's syndrome

(2011) Pierre Youinou et al.   ARTHRITIS RESEARCH & THERAPY

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

(2011) Hans-Peter Tony et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

Treatment of Primary Sjögren Syndrome

(2010) Manuel Ramos-Casals et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interleukin 6 and its soluble receptor in a central role at the neuroimmunoendocrine interface in Sjogren syndrome: an explanatory interventional study

(2009) H F. d'Elia et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome

(2009) J. Pijpe et al.   ARTHRITIS AND RHEUMATISM

Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse

(2009) Lianne C. Hsing et al.   JOURNAL OF AUTOIMMUNITY

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

(2009) Michael P. Cancro et al.   JOURNAL OF CLINICAL INVESTIGATION

Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

(2008) S Dass et al.   ANNALS OF THE RHEUMATIC DISEASES